Market Research Logo

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
B-Cell Chronic Lymphocytic Leukemia Overview
Therapeutics Development
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes
B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies
B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc.
Advancell
Amgen Inc.
BioNovion B.V.
Celgene Corporation
Dynavax Technologies Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Formula Pharmaceuticals, Inc.
iDD biotech SAS
Immunomedics, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
Nippon Shinyaku Co., Ltd.
Noxxon Pharma AG
Ono Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
SBI Biotech Co., Ltd.
TheraMAB LLC
Vivia Biotech, S.L.
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
202-b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB-8779 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acadesine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alemtuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-319 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bafetinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BION-1301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Hematological Malignancies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD16 for CLL and NHL - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD19 for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-7449 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GNKS-356 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDD-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDD-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-64052781 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAT-303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
olaptesed pegol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-4059 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REGN-1979 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SD-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAB-08 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vivia-009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones
Featured News & Press Releases
Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement
Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2015
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AbbVie Inc., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Advancell, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioNovion B.V., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Formula Pharmaceuticals, Inc., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by SBI Biotech Co., Ltd., H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Vivia Biotech, S.L., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2015
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H2 2015
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2015
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report